Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Staiger

Showing results (31-40 of 67) with videos related to

Pageof 7
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 26, 2021
SPARC-positive macrophages are the superior prognostic factor in the microenvironment of diffuse large B-cell lymphoma and independent of MYC rearrangement and double-/triple-hit statusG A Croci, R K H Au-Yeung, S Reinke, et al.
Genome Research|November 18, 2025
Integration of high-throughput proteomic data and complementary omics layers with PriOmicsRobin Kosch, Katharina Limm, Annette M Staiger, et al.
British Journal of Haematology|August 14, 2019
The impact of SOCS1 mutations in diffuse large B-cell lymphomaKevin Mellert, Melanie Martin, Jochen K Lennerz, et al.
Histopathology|November 9, 2020
Cytokeratin expression in plasmablastic lymphoma - a possible diagnostic pitfall in the routine work-up of tumoursKatrin S Huettl, Annette M Staiger, Heike Horn, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 29, 2021
Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphomaMarco Fangazio, Erik Ladewig, Karen Gomez, et al.
The Lancet. Haematology|March 5, 2021
Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trialFabian Frontzek, Marita Ziepert, Maike Nickelsen, et al.
International Journal of Cancer|June 15, 2017
TP53 mutation and survival in aggressive B cell lymphomaThorsten Zenz, Markus Kreuz, Maxi Fuge, et al.
Leukemia|January 5, 2023
Molecular profiling of EBV associated diffuse large B-cell lymphomaFabian Frontzek, Annette M Staiger, Ramona Wullenkord, et al.
Blood|August 22, 2018
Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profilesJohannes C Hellmuth, Abner Louissaint, Monika Szczepanowski, et al.
Hemasphere|March 10, 2025
Age- and gender-specific molecular characteristics of diffuse large B-cell lymphoma: Results from clinical trials of the DSHNHL/GLAKatrin S Kurz, Sophia Steinlein, Markus Kreuz, et al.
Pageof 7

Showing results (31-40 of 67) with videos related to

Sort By:
Pageof 7
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 26, 2021
SPARC-positive macrophages are the superior prognostic factor in the microenvironment of diffuse large B-cell lymphoma and independent of MYC rearrangement and double-/triple-hit statusG A Croci, R K H Au-Yeung, S Reinke, et al.
Genome Research|November 18, 2025
Integration of high-throughput proteomic data and complementary omics layers with PriOmicsRobin Kosch, Katharina Limm, Annette M Staiger, et al.
British Journal of Haematology|August 14, 2019
The impact of SOCS1 mutations in diffuse large B-cell lymphomaKevin Mellert, Melanie Martin, Jochen K Lennerz, et al.
Histopathology|November 9, 2020
Cytokeratin expression in plasmablastic lymphoma - a possible diagnostic pitfall in the routine work-up of tumoursKatrin S Huettl, Annette M Staiger, Heike Horn, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 29, 2021
Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphomaMarco Fangazio, Erik Ladewig, Karen Gomez, et al.
The Lancet. Haematology|March 5, 2021
Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trialFabian Frontzek, Marita Ziepert, Maike Nickelsen, et al.
International Journal of Cancer|June 15, 2017
TP53 mutation and survival in aggressive B cell lymphomaThorsten Zenz, Markus Kreuz, Maxi Fuge, et al.
Leukemia|January 5, 2023
Molecular profiling of EBV associated diffuse large B-cell lymphomaFabian Frontzek, Annette M Staiger, Ramona Wullenkord, et al.
Blood|August 22, 2018
Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profilesJohannes C Hellmuth, Abner Louissaint, Monika Szczepanowski, et al.
Hemasphere|March 10, 2025
Age- and gender-specific molecular characteristics of diffuse large B-cell lymphoma: Results from clinical trials of the DSHNHL/GLAKatrin S Kurz, Sophia Steinlein, Markus Kreuz, et al.
Pageof 7